Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 6, 2013 - Issue 3
Submit an article Journal homepage
132
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Fixed-dose combination of phentermine–topiramate for the treatment of obesity

Bruno Halpern Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil. [email protected]
,
André M Faria Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
&
Alfredo Halpern Obesity & Metabolic Syndrome Unit, Division of Endocrinology & Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
Pages 235-241 | Published online: 10 Jan 2014

References

  • Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 282(16), 1530–1538 (1999).
  • Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359(20), 2105–2120 (2008).
  • Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298(17), 2028–2037 (2007).
  • Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 348(17), 1625–1638 (2003).
  • James WP, Caterson ID, Coutinho W et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905–917 (2010).
  • Hebden L, Chey T, Allman-Farinelli M. Lifestyle intervention for preventing weight gain in young adults: a systematic review and meta-analysis of RCTs. Obes. Rev. 13(8), 692–710 (2012).
  • Martin PD, Dutton GR, Rhode PC, Horswell RL, Ryan DH, Brantley PJ. Weight loss maintenance following a primary care intervention for low-income minority women. Obesity (Silver Spring) 16(11), 2462–2467 (2008).
  • Smith SR, Weissman NJ, Anderson CM et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363(3), 245–256 (2010).
  • Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341–1352 (2011).
  • Halpern B, Oliveira ESL, Faria AM et al. Combinations of drugs in the treatment of obesity. Pharmaceuticals 3(8), 2398–2415 (2010).
  • Weintraub M, Sundaresan PR, Madan M et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin. Pharmacol. Ther. 51(5), 586–594 (1992).
  • Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337(9), 581–588 (1997).
  • Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes. Res. 8(6), 431–437 (2000).
  • Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr. Res. 30(2), 159–167 (2004).
  • Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 17(9), 1730–1735 (2009).
  • Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A. Recent progress and novel perspectives on obesity pharmacotherapy. Arq. Bras. Endocrinol. Metabol. 54(6), 516–529 (2010).
  • Halpern B, Faria AM, Halpern A. Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs Today 47(8), 575–581 (2011).
  • Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N. Engl. J. Med. 367(17), 1577–1579 (2012).
  • Rothman RB, Baumann MH, Dersch CM et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1), 32–41 (2001).
  • Mercer SL. ACS chemical neuroscience molecule spotlight on Qnexa. ACS Chem. Neurosci. 2(4), 183–184 (2011).
  • Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26(2), 262–273 (2002).
  • Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes. Obes. Metab. 12(10), 876–882 (2010).
  • Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 19(12), 2351–2360 (2011).
  • Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 37(Suppl. 6), S4–11 (1996).
  • Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 16(9), 2024–2038 (2008).
  • Caricilli AM, Penteado E, de Abreu LL et al. Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology 153(9), 4401–4411 (2012).
  • Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes. Rev. 12(5), e338–e347 (2011).
  • Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. Relat. Metab. Disord. 28(11), 1399–1410 (2004).
  • Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L; OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive Type 2 diabetes. Diabetes. Obes. Metab. 9(3), 360–368 (2007).
  • Leombruni P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr. Dis. Treat. 5, 385–392 (2009).
  • Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev. Cardiovasc. Ther. 8(12), 1777–1801 (2010).
  • Gadde KM, Yonish GM, Foust MS, Tam PY, Najarian T. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Obes. Res. 14(Suppl.) A17–A18 (2006).
  • Greenway FL, Fujioka K, Plodkowski RA et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 376(9741), 595–605 (2010).
  • Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. 95(2), 297–308 (2012).
  • Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20(2), 330–342 (2012).
  • Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 35(11), 1529–1539 (2012).
  • Vajda FJ, Graham J, Roten A, Lander CM, O’Brien TJ, Eadie M. Teratogenicity of the newer antiepileptic drugs – the Australian experience. J. Clin. Neurosci. 19(1), 57–59 (2012).
  • Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 111(1), 109–111 (2004).
  • Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr. Opin. Ophthalmol. 18(2), 129–133 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.